首页> 美国卫生研究院文献>Cancer Biotherapy Radiopharmaceuticals >Strengths and Weaknesses of a Planar Whole-Body Method of 153Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry
【2h】

Strengths and Weaknesses of a Planar Whole-Body Method of 153Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry

机译:153Sm剂量平面整体法对转移性骨肉瘤患者的优缺点及与三维剂量法的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose: Dosimetric accuracy depends directly upon the accuracy of the activity measurements in tumors and organs. The authors present the methods and results of a retrospective tumor dosimetry analysis in 14 patients with a total of 28 tumors treated with high activities of 153Sm-ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) for therapy of metastatic osteosarcoma using planar images and compare the results with three-dimensional dosimetry.>Materials and Methods: Analysis of phantom data provided a complete set of parameters for dosimetric calculations, including buildup factor, attenuation coefficient, and camera dead-time compensation. The latter was obtained using a previously developed methodology that accounts for the relative motion of the camera and patient during whole-body (WB) imaging. Tumor activity values calculated from the anterior and posterior views of WB planar images of patients treated with 153Sm-EDTMP for pediatric osteosarcoma were compared with the geometric mean value. The mean activities were integrated over time and tumor-absorbed doses were calculated using the software package OLINDA/EXM.>Results: The authors found that it was necessary to employ the dead-time correction algorithm to prevent measured tumor activity half-lives from often exceeding the physical decay half-life of 153Sm. Measured half-lives so long are unquestionably in error. Tumor-absorbed doses varied between 0.0022 and 0.27 cGy/MBq with an average of 0.065 cGy/MBq; however, a comparison with absorbed dose values derived from a three-dimensional analysis for the same tumors showed no correlation; moreover, the ratio of three-dimensional absorbed dose value to planar absorbed dose value was 2.19. From the anterior and posterior activity comparisons, the order of clinical uncertainty for activity and dose calculations from WB planar images, with the present methodology, is hypothesized to be about 70%.>Conclusion: The dosimetric results from clinical patient data indicate that absolute planar dosimetry is unreliable and dosimetry using three-dimensional imaging is preferable, particularly for tumors, except perhaps for the most sophisticated planar methods. The relative activity and patient kinetics derived from planar imaging show a greater level of reliability than the dosimetry.
机译:>目的:剂量学准确性直接取决于肿瘤和器官中活性测量的准确性。作者介绍了回顾性肿瘤剂量分析的方法和结果,对14例共计28例 153 Sm-乙二胺四亚甲基膦酸酯( 153 Sm-EDTMP ),用于通过平面图像治疗转移性骨肉瘤,并将结果与​​三维剂量学进行比较。>材料和方法:体模数据分析为剂量学计算提供了一套完整的参数,包括累积因子,衰减系数以及相机停滞时间补偿。后者是使用先前开发的方法获得的,该方法考虑了在全身(WB)成像期间相机和患者的相对运动。将根据 153 Sm-EDTMP治疗的小儿骨肉瘤患者的WB平面图像的前视图和后视图计算的肿瘤活动值与几何平均值进行比较。平均强度随时间积分,并使用OLINDA / EXM软件包计算肿瘤吸收剂量。>结果:作者发现,必须使用死区时间校正算法来防止测得的肿瘤活性的半衰期通常超过 153 Sm的物理衰变半衰期。如此长的测量半衰期无疑是错误的。肿瘤吸收剂量在0.0022至0.27 cGy / MBq之间变化,平均为0.065 cGy / MBq。然而,与对同一肿瘤进行三维分析得出的吸收剂量值的比较没有相关性。此外,三维吸收剂量值与平面吸收剂量值之比为2.19。从前后活动比较,假设使用本方法从WB平面图像进行活动和剂量计算的临床不确定性顺序约为70%。>结论:临床剂量学结果患者数据表明绝对平面剂量法是不可靠的,尤其是对于肿瘤,最好使用三维成像剂量法,最复杂的平面方法可能除外。从平面成像得出的相对活动和患者动力学比剂量测定法显示出更高的可靠性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号